Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 20/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13359650 | 0.97 | SLC6A2 (0.71) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3286827 | 0.89 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3291525 | 0.87 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3286857 | 0.87 | SLC6A2 (0.77) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3294833 | 0.86 | SLC6A2 (0.73) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3285470 | 0.85 | SLC6A2 (0.62) | SLC6A2SLC6A4 | |
| SCHEMBL3288900 | 0.84 | SLC6A2 (0.79) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3285414 | 0.84 | SLC6A2 (0.71) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13359666 | 0.84 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13359651 | 0.84 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718652-B2 | Substituted benzothiadiazinedioxide derivatives and methods of their use | WYETH LLC (US) | 2010-05-18 | — | — | US | claimed |
| US-20080161295-A1 | SUBSTITUTED BENZOTHIADIAZINEDIOXIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | claimed |
| US-7718652-B2 | Substituted benzothiadiazinedioxide derivatives and methods of their use | WYETH LLC (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718652-B2 | Substituted benzothiadiazinedioxide derivatives and methods of their use | WYETH LLC (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080161295-A1 | SUBSTITUTED BENZOTHIADIAZINEDIOXIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161295-A1 | SUBSTITUTED BENZOTHIADIAZINEDIOXIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161295-A1 | SUBSTITUTED BENZOTHIADIAZINEDIOXIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A2, SLC6A4, DBH | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.